EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Medical Therapy Versus Percutaneous Coronary Intervention in Patients with Myocardial Bridging from a National Population-Based Cohort Study: The Use of Big Data Analytics

Chayakrit Krittanawong, Song Peng Ang, Fernando Alexis Padilla, Yusuf Kamran Qadeer, Zhen Wang, Nicola Gaibazzi, Samin K. Sharma, Carl J. Lavie, Hartzell V. Schaff, Ernst R. Schwarz

Cardiogenetics · 09.04.2025 · 15 (2) · 10

DOI: 10.3390/cardiogenetics15020010 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Cardiogenetics, online erschienen am 09.04.2025. Verfasst von Chayakrit Krittanawong und 9 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myocardial Bridging (MB) is typically a benign congenital coronary anomaly. MB can infrequently result in complications such as myocardial ischemia, arrhythmias, and sudden cardiac death. Recent studies suggest an underlying genetic component for MB involving DES, FBN1, SCN2B, or NOTCH1. The role of percutaneous coronary intervention (PCI) in managing MB, compared to optimal medical therapy (OMT), remains uncertain. Our study used the National Inpatient Sample (NIS) Database to identify patients aged 18 or older with myocardial bridging who were managed with PCI versus medical therapy. We compared the outcomes between both groups including in-hospital mortality, the trend of management of MB and other in-hospital outcomes or complications. Our results showed no statistically significant difference between both subgroups when comparing in-hospital mortality and secondary outcomes of cardiac arrest and the development of an acute kidney injury (AKI). Patients with myocardial bridging treated with PCI had a higher risk of developing cardiogenic shock, requiring LVAD, and requiring the use of intra-aortic balloon pump (IABP) compared to the medical therapy subgroup. Our study suggests the decision to perform PCI in myocardial bridging patients should be individualized such as in patients with refractory symptoms despite medical therapy or those with known high-risk features.

Zitieren

APA

Krittanawong, C., Ang, S. P., Padilla, F. A., Qadeer, Y. K., Wang, Z., Gaibazzi, N., Sharma, S. K., Lavie, C. J., Schaff, H. V., & Schwarz, E. R. (2025). Medical Therapy Versus Percutaneous Coronary Intervention in Patients with Myocardial Bridging from a National Population-Based Cohort Study: The Use of Big Data Analytics. Cardiogenetics, 15(2), 10. https://doi.org/10.3390/cardiogenetics15020010

Vancouver

Krittanawong C, Ang SP, Padilla FA, Qadeer YK, Wang Z, Gaibazzi N, et al. Medical Therapy Versus Percutaneous Coronary Intervention in Patients with Myocardial Bridging from a National Population-Based Cohort Study: The Use of Big Data Analytics. Cardiogenetics. 2025;15(2):10. doi:10.3390/cardiogenetics15020010

BibTeX
@article{Krittanawong2025,
  author = {Krittanawong, Chayakrit and Ang, Song Peng and Padilla, Fernando Alexis and Qadeer, Yusuf Kamran and Wang, Zhen and Gaibazzi, Nicola and Sharma, Samin K. and Lavie, Carl J. and Schaff, Hartzell V. and Schwarz, Ernst R.},
  title = {Medical Therapy Versus Percutaneous Coronary Intervention in Patients with Myocardial Bridging from a National Population-Based Cohort Study: The Use of Big Data Analytics},
  journal = {Cardiogenetics},
  year = {2025},
  volume = {15},
  number = {2},
  pages = {10},
  doi = {10.3390/cardiogenetics15020010}
}
Kostenlos starten →